This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/mesh/concept/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01231/identifier/chemspider/
n16http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB01231/identifier/chebi/
n13http://www.drugs.com/cons/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01231/identifier/pharmgkb/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01231/identifier/kegg-compound/
owlhttp://www.w3.org/2002/07/owl#
n9http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01231/identifier/pubchem-compound/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB01231/identifier/pubchem-substance/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01231/identifier/kegg-drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01231/identifier/drugbank/

Statements

Subject Item
n2:DB01231
rdf:type
n5:Drug
n5:description
Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.
n5:generalReferences
# "Link":http://www.medicinenet.com/diphenidol_hcl-oral/article.htm
n5:group
withdrawn approved
n5:halfLife
4 hours
n5:indication
For use in the prevention and symptomatic treatment of peripheral (labyrinthine) vertigo and associated nausea and vomiting that occur in such conditions as Meniere's disease and surgery of the middle and inner ear. Also for the control of nausea and vomiting associated with postoperative states, malignant neoplasms, labyrinthine disturbances, antineoplastic agent therapy, radiation sickness, and infectious diseases.
owl:sameAs
n8:DB01231 n16:DB01231
dcterms:title
Diphenidol
adms:identifier
n4:C06961 n15:PA164746037 n17:4638 n18:2947 n20:3055 n21:46506486 n22:D03858 n23:DB01231
n5:mechanismOfAction
The mechanism by which diphenidol exerts its antiemetic and antivertigo effects is not precisely known. It is thought to diminish vestibular stimulation and depress labyrinthine function and as an antimuscarinic agent. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Diphenidol has no significant sedative, tranquilizing, or antihistaminic action. It has a weak peripheral anticholinergic effect.
n5:packager
n19:271B5ADD-363D-11E5-9242-09173F13E4C5
n5:synonym
Diphenidol Diphenyl(3-(1-piperidyl)propyl)carbinol Difenidol Difenidolum Difenidolo alpha,alpha-Diphenyl-1-piperidinebutanol
n5:toxicity
Symptoms of overdose include drowsiness (severe); shortness of breath or troubled breathing; unusual tiredness or weakness (severe).
n5:salt
n5:synthesisReference
Miescher, K. and Marxer, A.; U.S. Patent 2,411,664; November 26, 1946; assigned to Ciba Pharmaceutical Products, Inc.
n9:hasConcept
n10:M0046072
foaf:page
n13:diphenidol.html
n5:IUPAC-Name
n6:271B5AE3-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5AE9-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5AE8-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5AE5-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5AE6-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5AE7-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5AE1-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5AFA-363D-11E5-9242-09173F13E4C5 n6:271B5AE2-363D-11E5-9242-09173F13E4C5 n6:271B5ADF-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5AE0-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B5AEF-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5AF0-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5AEA-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5AEB-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5AED-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5AEC-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5AEE-363D-11E5-9242-09173F13E4C5
n5:absorption
Well absorbed from gastrointestinal tract following oral administration.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
972-02-1
n5:category
n5:containedIn
n11:271B5ADE-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5AF5-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5AF7-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5AF8-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B5AF9-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5AF4-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5AF3-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5AF6-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5AE4-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5AF1-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5AF2-363D-11E5-9242-09173F13E4C5